Regulatory approval

Published by the Health Service Executive. Approved

As a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy

This is written in the approval document.

Reimbursement

ODMS

Citation

Trastuzumab Emtansine (Kadcyla) Early Breast Cancer Therapy - 21 days, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6680/659_v2_Trastuzumab_Emtansine_EBC_21days.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2021-12-20	Health Service Executive	Indication approved for reimbursement.